Inc.

Deloitte is ending insurance coverage for GLP-1 weight-loss medications and increasing deductibles and out-of-pocket limits for many U.S. employees starting January 2027.
Deloitte Is Dropping Weight-Loss Drug Coverage. Employees Will Pay More in 2 Other Ways
Author: Sadiya Kherani
As we get closer to the new year, more and more companies are announcing rising healthcare coverage costs and changing plans, Deloitte is the latest one.
According to an internal benefits guide obtained by Business Insider, starting January, Deloitte will no longer cover GLP-1 medication for weight-loss through its medical plans for U.S. employees.
This benefit guide applies to what Deloitte calls its, “Core, Domain and Enterprise professionals,” this includes client-facing accountants, consultants and technical specialists. The company has about 181,000 employees in the U.S.
On top of the reduced GLP-1 coverage, U.S. employees will also be required to pay higher deductibles and out-of-pocket maximums under most of Deloitte’s health plans, according to the document. This means the costs will be higher for plan users before and after the coverage activates.
Corporate America as a whole has been struggling with rising health care costs and changing health care plans for both employees and employers over this past year.
These changes, “reflect the hard trade-offs of today’s cost environment,” Deloitte told the staff in the document. They continued saying there was a need, “for shared responsibility in a few specific places where it’s become untenable for Deloitte to carry the cost alone.”
Deloitte will continue to cover GLP-1 medications though for anyone using it as prescribed for diabetes and other medical conditions. The Big Four firm is also offering employees seeking support for weight loss access to a virtual lifestyle program called eMed that includes coaching and a cost of $125 per prescription of employee contribution.
The list price of common GLP-1s can exceed $1,000 although purchasing them through direct programs such as LillyDirect or government plans like TrumpRx significantly lower the costs as well. For example TrumpRx offers semaglutide injection pens under Ozempic for between $199 and $499.
On top of all these changes, Deloitte is expanding some of their healthcare coverage. This includes improving long-term disability protection and adding free annual eye exams to its company-paid discount vision program.
It’s has been a tough year for health benefits. According to a survey from KFF, workers on a family plan paid on average $7,471 this year in premiums which is 9 percent higher than 2025. This means that in 2026 employee premiums for a family plan totalled to about $28,303, after accounting for employer contributions which is about a 5 percent increase from 2025.
Credits: TCA, LLC.